Full year results

Full year results

Manchester, UK – 26 November 2019 - SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”) a life sciences company focused on skin health, has announced its full year audited results for the year to 30 June 2019.


Key highlights

  • Successful completion of first human cosmetic study
  • Strengthened board and management team, including appointment of Stuart Ashman as CEO
  • Strategic review has identified five channels of focus for development, encompassing both existing and new technology
  • Cash as at 30 June 2019 of £3.1m (2018: £3.2m), cash levels raised by share placing raising an additional £1.5m
  • Post year end: first commercial and manufacturing agreement signed with Croda International Plc 


Stuart Ashman, CEO of SkinBioTherapeutics, said:

“This has been an exciting year for the Company. The beginning of the year was about proving the sound scientific foundation of our SkinBiotix® technology and the positive effects of it on the barrier function of the skin. The successful results drove commercialisation discussions forward which resulted in our recent agreement with the world leader in skincare actives for the cosmetic industry, Croda International plc. We will continue to seek further commercial opportunities and build the development pipeline with new programmes in eczema and psoriasis during 2020.” 

26th November, 2019
investors logo